Announcements
- Addex to Present at Bio€quity Europe 2024
- Addex Provides Update on ADX71149 Phase 2 Epilepsy Study
- Addex to Present at the Swiss Biotech Day 2024
- Addex Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
- Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024
- Addex and Perceptive Launch Neurosterix with $63 Million to Accelerate Development of Allosteric Modulator Therapeutics for Neurological Disorders
- Addex to Present at the Bio-Europe Spring 2024 Conference
- Addex Enters into At-The-Market ADS Offering Agreement with H.C. Wainwright & Co. LLC.
- Addex to Present at the Swiss Equities Baader Conference
- Addex to Present at Biotech Showcase™ 2024
More ▼
Key statistics
On Saturday, Addex Therapeutics Ltd (0QNV:LSE) closed at 0.00, -100.00% above its 52-week low of 0.0554, set on Jan 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 0.064 |
Average volume | -- |
---|---|
Shares outstanding | 184.35m |
Free float | 149.13m |
P/E (TTM) | -- |
Market cap | 12.54m CHF |
EPS (TTM) | -0.1433 CHF |
Data delayed at least 20 minutes, as of Dec 30 1899.
More ▼